Re:Cognition Health is enrolling volunteers to participate in studies.

Current Studies

The Green Memory Study (Phase III)

The Green Memory study is researching an investigational medication designed to rebalance certain bacteria in the gut, as previous research has shown an imbalance in gut bacteria could be linked to Alzheimer’s and other diseases. The investigational medication has been researched and approved in other countries, where it was proven to be safe and effective. The investigational medication works to rebalance good gut bacteria, reducing brain inflammation and effects relevant to AD.

You can learn more about the Green Memory Study at the following link or the video below: https://www.greenmemoryalzstudy.com/

You or a loved one may participate in the Green Memory Study if you/they:

  • Are 50-85 years of age
  • Have mild to moderate AD
  • Have a study partner who knows the participant well and can come to all study-related visits and is with them 3 or more days a week

The FOUND Study (Phase III)

The FOUND study is researching the effect of the oral drug fasudil which may improve blood flow in the brain and improve memory pertaining to location and navigation. The purpose of the FOUND study is to help learn whether fasudil reduces wandering in subjects with dementia. The study will also assess effects of fasudil on thinking, memory, emotional symptoms, and caregiver/nursing staff burden, as well as how well fasudil is tolerated and how safe it is.

You or a loved one may participate in the FOUND Study if you/they:

  • 50 to 90 years of age 
  • Diagnosis of dementia of any etiology
  • Mini Mental State Examination score of 9-24
  • Presence of one or both of the following wandering behaviors of at least of moderate severity:
    • Elopes or attempts to elope
    • Gets lost or is unable to locate a specific place
  • Has a caregiver who has more than 10 hours/week of contact with the subject who is fluent in English and is willing to accept responsibility for supervising the treatment and assessing the condition of the subject throughout the study

Not sure if you qualify? Register and we’ll reach out to you to find out.

 

The Apollo Study (Phase II)

This study researches the oral investigational drug’s ability to stop or slow Alzheimer’s disease progression and the onset of symptoms in carriers of the APOE4/4 homozygous gene. Patients who hold this gene are more susceptible to AD. This investigational drug is positioned to be the first oral medication to stop or slow the progression of Alzheimer’s disease.

You or a loved on may participate in the Apollo Study if you/they are:

  • At high-risk APOE4/4 homozygous patients with Early AD
  • 50 to 80 years of age

We are providing free genetic tests to qualified individuals to see if they have the APOE4/4 homozygous gene. Register for a free test and no commitment to participate in the trial.

 

The LUCIDITY Study (Phase III)

This clinical research study aims to evaluate an investigational drug in men and women with early Alzheimer’s disease (AD). Currently, a limited number of approved treatments help with the symptoms of AD, but do not stop the disease from progressing. By reducing the build-up of ‘tau tangles’ in the brain, the main driver of AD, researchers believe that this investigational drug could help slow disease progression and enhance quality of life for people with AD.

You or a loved one may be able to participate in the LUCIDITY study if you/they:

  • Are under 90 years of age
  • Are experiencing memory loss or changes, or have been diagnosed with:
    • MCI (Mild Cognitive Impairment), or
    • Probable or Early Alzheimer’s disease, or
    • Mild/Moderate Alzheimer’s disease
  • Have a study partner who can assist with study participation

The GAIN Study (Phase II)
– A Revolutionary New Approach to Understanding Alzheimer’s

The GAIN Trial is based on the growing body of scientific evidence that the bacteria P. gingivalis, commonly associated with gum disease, can infect the brain and cause Alzheimer’s disease. COR388 is an investigational drug designed to inactivate toxic proteins released by the bacteria and stop or slow further damage to healthy brain cells. A study of COR388 in a small group of Alzheimer’s patients has shown promise in improving memory. GAIN is a clinical trial evaluating whether an investigational oral drug is safe and can halt the progression of Alzheimer’s disease by reducing the damage caused by bacteria in the brain.

You or a loved one may be eligible for the study if you:

  • Are 55 to 80 years old
  • Have been diagnosed with mild to moderate Alzheimer’s disease
  • Have a caregiver or family member who will attend study visits, report on daily activities and oversee you taking medication

Our team of Brain and Mind Experts at Re:Cognition Health are dedicated to research and are focused on paving the way for a future without Alzheimer’s disease. With every study undertaken we come closer to finding out more about Alzheimer’s disease and finding new treatments.

To register interest to participate in a clinical trial click the button below:

Interest Form

  • Submit your interest to our team of specialists